Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia
| Autor: | Vania Manolova, Cédric Doucerain, Naja Nyffenegger, Franz Dürrenberger, Patrick Altermatt, Hanna Sundström, Anna Flace, Ahmet Varol |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Ineffective erythropoiesis Male Myeloid Thalassemia Ferroportin Drug Evaluation Preclinical Administration Oral beta-Globins Pharmacology medicine.disease_cause Ferric Compounds Madin Darby Canine Kidney Cells Rats Sprague-Dawley Mice 0302 clinical medicine Oral administration hemic and lymphatic diseases Erythropoiesis Cation Transport Proteins biology General Medicine medicine.anatomical_structure 030220 oncology & carcinogenesis Female Research Article congenital hereditary and neonatal diseases and abnormalities Anemia Iron Cell Line 03 medical and health sciences Dogs Hepcidins Hepcidin medicine Animals Humans Maltose business.industry beta-Thalassemia Ubiquitination medicine.disease Mice Mutant Strains Mice Inbred C57BL Disease Models Animal 030104 developmental biology Proteolysis biology.protein business |
| Popis: | β-Thalassemia is a genetic anemia caused by partial or complete loss of β-globin synthesis, leading to ineffective erythropoiesis and RBCs with a short life span. Currently, there is no efficacious oral medication modifying anemia for patients with β-thalassemia. The inappropriately low levels of the iron regulatory hormone hepcidin enable excessive iron absorption by ferroportin, the unique cellular iron exporter in mammals, leading to organ iron overload and associated morbidities. Correction of unbalanced iron absorption and recycling by induction of hepcidin synthesis or treatment with hepcidin mimetics ameliorates β-thalassemia. However, hepcidin modulation or replacement strategies currently in clinical development all require parenteral drug administration. We identified oral ferroportin inhibitors by screening a library of small molecular weight compounds for modulators of ferroportin internalization. Restricting iron availability by VIT-2763, the first clinical stage oral ferroportin inhibitor, ameliorated anemia and the dysregulated iron homeostasis in the Hbb(th3/+) mouse model of β-thalassemia intermedia. VIT-2763 not only improved erythropoiesis but also corrected the proportions of myeloid precursors in spleens of Hbb(th3/+) mice. VIT-2763 is currently being developed as an oral drug targeting ferroportin for the treatment of β-thalassemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|